MiR-125b predicts childhood acute lymphoblastic leukaemia poor response to BFM chemotherapy treatment.

ABSTRACT:

Background

Despite the favourable survival rates of childhood acute lymphoblastic leukaemia (ALL), a significant number of patients present resistance to antileukaemic agents and dismal prognosis. In this study, we analysed miR-125b expression in childhood ALL and evaluated its clinical utility for patients treated with Berlin-Frankfurt-Münster (BFM) protocol.

Methods

The study included 272 bone marrow specimens obtained on diagnosis and on BFM day 33 from 125 patients and 64 healthy children. Following extraction, RNA was polyadenylated and reverse transcribed. miR-125b levels were quantified by quantitative PCR. Cytogenetics, immunohistotype and MRD were analysed according to international guidelines.

Results

Downregulated miR-125b levels were detected in childhood

SUBMITTER: Piatopoulou D 

PROVIDER: S-EPMC5589998 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature